Matica Bio Signs Adenovirus CDMO Contract with North American Medical Research Institution
Supporting the Entire Process from Initial Development to Production
Cha Biotech announced on March 26 that its U.S. subsidiary, Matica Bio, has signed a contract for contract development and manufacturing organization (CDMO) services with a North American medical research institution for an adenovirus-based therapeutic.
Under this agreement, Matica Bio will support the entire process for the therapeutic currently under development by the institution, from initial process development to clinical production. This includes establishing research cell lines, process and analytical development, quality testing, creation of a virus bank, and cGMP manufacturing.
The company plans to expand its adenoviral vector production capabilities and strengthen its CDMO business foundation through this contract.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Matica Bio is a subsidiary established in the United States by Cha Biotech to conduct cell and gene therapy (CGT) CDMO business. It operates a manufacturing facility in College Station, Texas.
Based on its analytical and process development capabilities, the company is increasing its contracts in the CGT sector.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.